Annovis Bio Stock Performance
| ANVS Stock | USD 2.70 0.11 3.91% |
On a scale of 0 to 100, Annovis Bio holds a performance score of 7. The firm shows a Beta (market volatility) of -0.0681, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Annovis Bio are expected to decrease at a much lower rate. During the bear market, Annovis Bio is likely to outperform the market. Please check Annovis Bio's treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Annovis Bio's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Annovis Bio are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Annovis Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Five Day Return (6.90) | Year To Date Return (26.03) | Ten Year Return (71.85) | All Time Return (71.85) |
1 | Annovis Bio, Inc. Given Average Recommendation of Hold by Brokerages | 11/12/2025 |
2 | Acquisition by Michael Hoffman of 15000 shares of Annovis Bio at 2.11 subject to Rule 16b-3 | 11/14/2025 |
3 | Acquisition by Michael Hoffman of 10000 shares of Annovis Bio at 3.49 subject to Rule 16b-3 | 11/21/2025 |
4 | Annovis Announces Two Presentations at the CTAD 2025 Conference | 11/24/2025 |
5 | Annovis Bio, Inc. Receives Consensus Rating of Hold from Brokerages - MarketBeat | 12/01/2025 |
6 | Why Annovis Bio Inc. stock is a must watch ticker - Earnings Risk Report Weekly Watchlist for Consistent Profits - Newser | 12/05/2025 |
7 | Acquisition by Michael Hoffman of 30000 shares of Annovis Bio at 4.3398 subject to Rule 16b-3 | 12/08/2025 |
8 | Amyotrophic Lateral Sclerosis Market Outlook Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period DelveInsight | 12/09/2025 |
9 | Annovis Announces Open-Label Extension Study for Parkinsons Disease Patients | 12/18/2025 |
10 | Annovis Bio stock hits 52-week low at 4.05 amid market challenges - MSN | 01/05/2026 |
11 | Annovis Bio, Inc. Receives Average Recommendation of Hold from Analysts - MarketBeat | 01/21/2026 |
12 | Regulatory Milestones Could Shape Annovis Bios Clinical Trajectory - AD HOC NEWS | 01/28/2026 |
Annovis Bio Relative Risk vs. Return Landscape
If you would invest 204.00 in Annovis Bio on November 5, 2025 and sell it today you would earn a total of 66.00 from holding Annovis Bio or generate 32.35% return on investment over 90 days. Annovis Bio is currently generating 0.7057% in daily expected returns and assumes 7.2572% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Annovis, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Annovis Bio Target Price Odds to finish over Current Price
The tendency of Annovis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.70 | 90 days | 2.70 | about 77.16 |
Based on a normal probability distribution, the odds of Annovis Bio to move above the current price in 90 days from now is about 77.16 (This Annovis Bio probability density function shows the probability of Annovis Stock to fall within a particular range of prices over 90 days) .
Annovis Bio Price Density |
| Price |
Predictive Modules for Annovis Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Annovis Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Annovis Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Annovis Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Annovis Bio is not an exception. The market had few large corrections towards the Annovis Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Annovis Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Annovis Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.58 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 0.86 | |
Ir | Information ratio | 0.07 |
Annovis Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Annovis Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Annovis Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Annovis Bio is way too risky over 90 days horizon | |
| Annovis Bio appears to be risky and price may revert if volatility continues | |
| Annovis Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (24.59 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annovis Bio currently holds about 35.97 M in cash with (21.89 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Annovis Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Regulatory Milestones Could Shape Annovis Bios Clinical Trajectory - AD HOC NEWS |
Annovis Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Annovis Stock often depends not only on the future outlook of the current and potential Annovis Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Annovis Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.2 M | |
| Cash And Short Term Investments | 10.6 M |
Annovis Bio Fundamentals Growth
Annovis Stock prices reflect investors' perceptions of the future prospects and financial health of Annovis Bio, and Annovis Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Annovis Stock performance.
| Return On Equity | -3.65 | ||||
| Return On Asset | -1.12 | ||||
| Current Valuation | 59.19 M | ||||
| Shares Outstanding | 26.11 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 5.66 X | ||||
| EBITDA | (26.69 M) | ||||
| Net Income | (24.59 B) | ||||
| Cash And Equivalents | 35.97 M | ||||
| Cash Per Share | 4.41 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | (0.31) % | ||||
| Current Ratio | 28.11 X | ||||
| Book Value Per Share | 0.66 X | ||||
| Cash Flow From Operations | (21.89 B) | ||||
| Earnings Per Share | (2.10) X | ||||
| Market Capitalization | 59.8 M | ||||
| Total Asset | 13.93 M | ||||
| Retained Earnings | (134.85 M) | ||||
| Working Capital | 10.04 M | ||||
| Current Asset | 986 K | ||||
| Current Liabilities | 216 K | ||||
About Annovis Bio Performance
Assessing Annovis Bio's fundamental ratios provides investors with valuable insights into Annovis Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Annovis Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.59) | (1.67) | |
| Return On Capital Employed | (3.06) | (2.90) | |
| Return On Assets | (1.59) | (1.67) | |
| Return On Equity | (2.38) | (2.26) |
Things to note about Annovis Bio performance evaluation
Checking the ongoing alerts about Annovis Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Annovis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Annovis Bio is way too risky over 90 days horizon | |
| Annovis Bio appears to be risky and price may revert if volatility continues | |
| Annovis Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (24.59 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annovis Bio currently holds about 35.97 M in cash with (21.89 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Annovis Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Regulatory Milestones Could Shape Annovis Bios Clinical Trajectory - AD HOC NEWS |
- Analyzing Annovis Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Annovis Bio's stock is overvalued or undervalued compared to its peers.
- Examining Annovis Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Annovis Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Annovis Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Annovis Bio's stock. These opinions can provide insight into Annovis Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.